Navigation Links
New enzyme targets for selective cancer therapies
Date:8/22/2014

euraminidase enzyme in cancer cells is just the first step in determining its potential as a therapy.

In its current form, the compound could not be used as a drug, Cairo explained, largely because it wasn't designed to breach the blood-brain barrier making it difficult to reach the target cells. The team in Milan had to use the compound in very high concentrations, he added.

The research advances our understanding of how important carbohydrates are to the function of cells. Although most of us think of glucose (blood sugar) as the only important sugar in biology, there is an entire area of research known as glycobiology that seeks to understand the function of complex carbohydrate structures in cells. Carbohydrate structures cover the surface of cells, and affect how cells interact with each other and with pathogens.

Scientists have known for decades that the carbohydrates found on cancer cells are very different from those on normal cells. For example, many cancers have different amounts of specific residues like sialic acid, or may have different arrangements of the same residues.

"The carbohydrates on the cell surface determine how it interacts with other cells, which makes them important in cancer and other diseases. So, if we can design compounds that change these structures in a defined way, we can affect those interactions," Cairo explained. "Finding new enzyme targets is essential to that process, and our work shows that we can selectively target this neuraminidase enzyme."

Although there has been a lot of work on targeting viral neuraminidase enzymes, Cairo's team has found inhibitors of the human enzymes. "The challenge in human cells is that there are four different isoenzymes. While we might want to target one for its role in cancer, hitting the wrong one could have harmful side-effects," he said.

The U of A team reached out to their colleagues in Milan who were studying the role of a specific neur
'/>"/>

Contact: Bryan Alary
bryan.alary@ualberta.ca
780-492-0436
University of Alberta
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Penn biologists identify a key enzyme involved in protecting nerves from degeneration
2. New immune defense enzyme discovered
3. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
4. ORNL process improves catalytic rate of enzymes by 3,000 percent
5. Scientists discover enzyme that could slow part of the aging process in astronauts -- and the elderly
6. New screening technique yields elusive compounds to block immune-regulating enzyme
7. UCLA scientists discover how key enzyme involved in aging, cancer assembles
8. Is it a rock, or is it Jell-O? Defining the architecture of rhomboid enzymes
9. Brain enzyme is double whammy for Alzheimers disease
10. Ancient enzymes function like nanopistons to unwind RNA
11. Remarkable enzyme points the way to reducing nitric acid use in industry
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New enzyme targets for selective cancer therapies
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
(Date:6/8/2015)... , June 8, 2015  The Secure ... their selection of Troy Potter of ... immediately. SIBA is a non-profit association that was ... policy, education and implementation of solutions that protect ... ...
(Date:6/4/2015)... the co-chairs of the Blue Ribbon Study Panel on Biodefense ... USA Today,s investigative report ... findings of lax safety standards and called on the federal ... "The state of oversight of ... Lieberman , former senator and co-chair of the Blue Ribbon ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 2Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 3
... September 8, 2008For allergy sufferers, the choice all too ... curtains or anything that could trigger indoor allergens. ... with the launch of Clorox® Anywhere® Anti-Allergen Fabric Spray, ... fabric surfaces in the home. Clorox® Anywhere® ...
... Francis S. Collins, M.D., Ph.D., a physician-geneticist and ... with the new Inamori Ethics Prize from the Inamori ... Reserve University. Modeled after the Nobel and Kyoto ... Inamori Ethics Prize instead honors outstanding international ethical leaders. ...
... headed by Prof. Daniel Rosenfeld of the Institute of ... come up with a surprising finding to the disputed ... The conclusion: both can be true, depending on local ... is one with significant consequences in an era of ...
Cached Biology News:The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Leader of Human Genome Project honored with the Inamori Ethics Prize 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate ... is now offering a full suite of new genetic testing ... a biopsy, for diagnosing prostate cancer. ... of genetic tests for assessing the risk and optimizing the ... "We,re very excited to now offer these revolutionary genetic ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
(Date:6/29/2015)... 29, 2015  AACC, a global scientific and ... laboratory medicine, is pleased to announce that the ... , has increased to 7.9 in the 2014 ... Clinical Chemistry in the top 3% ... influence of the research it publishes on laboratory ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today ... 2007 financial results after the NASDAQ Global Market ... Jack Lief, Arena,s,President and Chief Executive Officer, and ... Financial Officer, will host a conference call,at 5:00 ...
... Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, development and,commercialization ... liver diseases, has announced the completion of a,$35.5 million Series ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that total revenue for the year,ending December 31, ... for the year ended December 31, 2006. Revenue from ... for full year,2007, an increase of 15% over core ...
Cached Biology Technology:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 2Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 3Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: